Faster Recovery of Internal Ophthalmoplegia than External Ophthalmoplegia in a Miller Fisher Variant of Guillain-Barre Syndrome

Golla Abhinav,1 Jorge Gamez Jr.,1 Michael C. Yang,1 Tetyana Vaysman,2 Michelle von Gunten,1 and Antonio Liu1

1Department of Neurology, Adventist Health White Memorial, Los Angeles, California, USA
2Department of Internal Medicine, University of Maryland, Cheverly, Maryland, USA

Correspondence should be addressed to Antonio Liu; liuak@ah.org

Received 16 February 2020; Accepted 18 March 2020; Published 13 April 2020

Academic Editor: Huban Atilla

Copyright © 2020 Golla Abhinav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We present a case of classic Miller Fisher Syndrome (MFS) variant of Guillain-Barre Syndrome (GBS) with detailed description in the difference between the internal and external ophthalmoplegia. They are different in their onset, duration, and recovery.

1. Introduction

MFS variant of GBS is associated with both the internal and external ophthalmoplegia [1]. Prior studies have noted that the defect in pupillary reactivity can vary with time [2]. With the pupillometer (NeurOptics NPi®-200), it is now possible to accurately and consistently measure pupillary size and reactivity. Ultimately, this device allows clinicians to objectively quantify pupillary function with the standardized Neurological Pupil Index (NPi) Pupil Reactivity Assessment Scale.

The pupillometer is an easy-to-use, handheld device that can be used at bedside. It is loaded with a SmartGuard cartridge and held up to the patient’s eye. The device accurately and consistently measures pupillary size and reactivity speed. The Neurological Pupil Index (NPi) Pupil Reactivity Assessment Scale scores range from 0 to 4.9. A score of 0 represents a nonreactive, immeasurable, or atypical response. A score of less than 3.0 indicates abnormal (“sluggish”) reactivity. A score of 3.0-4.9 indicates normal (“brisk”) reactivity. Additionally, a NPi score difference that is greater than or equal to 0.7 between the right- and left-eye measurements suggests a pupillary abnormality.

Currently, the literature describing the rate of recovery of the internal and external ophthalmoplegia in MFS is scarce.
all directions. During this time, he also developed bilateral ptosis. Pupillary size and reactivity were measured daily using the pupillometer. During hospital day one and two, pupillary function remained relatively normal (right NPi 2.6 “borderline sluggish,” left NPi 3.2 “brisk”). However, on hospital day three, pupillometer readings suggested that the patient’s pupils were “sluggish” bilaterally (right NPi 0.7, left NPi 0.8) (Figure 1).

The table shows the recorded pupil size and corresponding NPi score over the course of the patient’s admission. The adjacent graphs represent the recorded measurements through time (the gray lines indicate pupil size (in mm), blue line indicates right NPi, and red line indicates left NPi).

Throughout the hospital course, the patient’s nasal tone remained unchanged, but he developed moderate to severe dysarthria and minimal to moderate dysphagia. The patient’s extremity and truncal ataxia continued to worsen, and he subsequently required moderate assistance with a walker to ambulate. Sensation to light touch, temperature (ice examination), and proprioception remained intact. However, he reported tingling and “skin tightness” that persisted for over one week. The patient never developed urinary or bowel incontinence. He denied shortness of breath, maintained a normal vital capacity, and exhibited normal arterial blood gas studies.

Ganglioside antibody panel was sent out on hospital day one and resulted on hospital day ten, which was remarkable for elevated antibody levels (Asialo-GM1 Ab 279, GD1a Ab 52, and GQ1b Ab 273). Due to a high suspicion for an autoimmune neuromuscular disease, plasma exchange was initiated on hospital day three. A total of five plasmapheresis treatments were administered. The patient developed orthostatic hypotension on several occasions that led to two syncopal episodes, both within an hour of plasma exchange treatment. Pupillary reactivity recovered within four days of symptom onset (by hospital day seven); however, it took several weeks for external ophthalmoplegia to resolve (Figure 1).

The patient was discharged home on hospital day twenty. At the time of discharge, his external ophthalmoplegia persisted with only partial recovery. Six weeks after discharge, the patient’s symptoms had completely resolved and antibody levels had normalized (Asialo-GM1 Ab 50, GD1a Ab 18, and GQ1b Ab 48).

3. Discussion

Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barre Syndrome (GBS), occurring in 1-7% of GBS cases worldwide [3] and 5% of GBS cases in Western countries [4]. Early ocular findings of MFS and GBS include ophthalmoplegia, diplopia, and pupillary abnormalities (internal ophthalmoplegia)—all of which have been well described in the literature. However, at the time of authorship, the natural history of pupillary deficits and external ophthalmoplegia in MFS has not yet been objectively described in the literature.

The literature contains many references of MFS presentation, with both a typical triad of ophthalmoplegia, areflexia, and ataxia and atypical variants of MFS different.
in combination of symptoms. Kaymakamzade et al. have reported an interesting case of atypical MFS in a 17-year-old male patient, confirmed by raised titers of anti-GQ1b antibodies with an early onset of external ophthalmoplegia following by internal ophthalmoplegia and characterized by mydriasis and decreased reactivity to light [5]. Lopez et al. [6] have described a case of a 74-year-old woman with a sole presentation of internal ophthalmoplegia evidenced by non-reactive midsized pupils with preserved visual acuity as initial manifestation of MFS. The patient developed external ophthalmoplegia, mild ataxia, and hyporeflexia by the second day of the initial presentation and full resolution in two months [6]. These cases are interesting in demonstrating sequence of presentation, whereas out investigation is unique in focusing on difference in onset, duration, and recovery rate between the internal and external ophthalmoplegia.

This case report demonstrates that the internal and external ophthalmoplegia can occur together in MFS but are independent of each other in terms of onset, severity, and duration. Man [1] describes the case of a 46-year-old patient with total internal and external ophthalmoplegia as the initial presenting symptoms of MFS, confirmed with serum-positive anti-GQ1b antibodies. Serum anti-GQ1b antibodies are associated with GBS and MFS. GQ1b is a ganglioside that is commonly found in cell membranes of cranial nerves that innervate extracocular muscles (oculomotor, trochlear, and abducens nerve), confirmed by immunohistochemical studies [7]. Evidence strongly suggests that the ophthalmoparesis in MFS results from a direct action of anti-GQ1b antibodies on the presynaptic neuromuscular junction (NMJ) between cranial nerves and extraocular muscles [8]. Anti-GQ1b antibodies bind to presynaptic receptors which trigger a large release of acetylcholine and ultimately impair NMJ function [8]. Additionally, GQ1b gangliosides are also found in the ciliary ganglion, which is a presynaptic ganglion responsible for pupillary sphincter and ciliary muscle control [8]. These mechanisms may explain the prevalence of the internal and external ophthalmoplegia in MFS and GBS.

The use of a pupillometer in our presented case allowed for objective measurements of pupillary size and reactivity over the disease course of MFS. The patient’s pupillary reactivity worsened acutely on hospital day three and resolved after four days (hospital day seven) (Figure 1). External ophthalmoplegia reached its nadir on hospital day seven, continued to persist on hospital day twenty with only minor improvement, and eventually resolved after several weeks. The patient’s symptoms were completely resolved by the six-week follow-up appointment after discharge. This case report of Miller Fisher Syndrome (MFS), with positive anti-GQ1b antibodies, objectively documents the natural history of the internal and external ophthalmoplegia and demonstrates that these two entities can be independent of each other with regard to disease onset, severity, and duration.

**Ethical Approval**

The case report has been approved by the IRB and has received ethical approval. The case report and all conducted studies adhere to the Declaration of Helsinki.

**Consent**

Informed written consent was obtained from the patient for publication of this case report.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest regarding the publication of this case report.

**References**

[1] B. L. Man, “Total internal and external ophthalmoplegia as presenting symptoms of Miller Fisher syndrome,” *Case Reports*, vol. 2014, 2014.

[2] G. Gupta and A. Liu, “Atypical Miller Fisher syndrome with anisocoria and rapidly fluctuating pupillary diameter,” *Case Reports in Neurological Medicine*, vol. 2015, Article ID 472843, 2 pages, 2015.

[3] J. W. Teener, “Miller Fisher’s syndrome,” *Seminars in Neurology*, vol. 32, no. 5, pp. 512–516, 2012.

[4] M. M. Dimachkie and R. J. Barohn, “Guillain-Barré syndrome and variants,” *Neurologic Clinics*, vol. 31, no. 2, pp. 491–510, 2013.

[5] B. Kaymakamzade, F. Selcuk, A. Koysuren, A. I. Colpak, S. E. Mut, and T. Kansu, “Pupillary involvement in Miller Fisher syndrome,” *Neuro-Ophtalmology*, vol. 37, no. 3, pp. 111–115, 2013.

[6] T. Lopez, S. Mur, A. M. Gutierrez Alvarez, and C. Jimenez, “Oftalmoplejía interna como comienzo de un síndrome de Miller-Fisher,” *Neurología*, vol. 29, no. 8, pp. 504-505, 2014.

[7] A. Chiba, S. Kusunoki, H. Obata, R. Machinami, and I. Kanazawa, “Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies,” *Neurology*, vol. 43, no. 10, pp. 1911–1917, 1993.

[8] J. B. Winer, “Guillain Barre syndrome,” *Molecular pathology*, vol. 54, pp. 381–385, 2001.